To successfully deliver innovative and life-changing therapies, you need high-quality products and services that push what’s possible and meet regulatory compliance.

That’s where we come in.

We are committed to providing our partners with the flexibility to choose from advanced technology platforms and unique service models to meet specific project needs.

With our assay-ready iLite reporter cells and custom reporter cell line engineering services in combination with our bioassay development and validation services (GMP) we can accompany you on your way to a late potency assay.

Feel free to reach out to our experts present at the BEBPA US Bioassay Conference 2025 to discuss your program 

Talk to us today!

Meet our Team of Experts! 

Don't miss our Poster Presentations

←  Quantification of bispecific antibody-mediated T-cell activation with engineered CD3 effector and tailored target cells
Authors: Ulrich Mayer, Frier Bovin L, Gobbo E, Ferrando-Miguel R, Lallemand C

Development of a Potency Assay for an AAV-Encoded Transgene Regulated by Retina-Specific Promoters Using the iLite® Reporter-Gene Technology  →
Authors: Tovey M, Mayer U, Schwenkert M, Huang L, Lallemand C, Rodó J

Potency Testing 

We perform both GMP and non-GMP analysis of Biologics and Biosimilar samples from development and manufacturing. Our services include method development, qualification, validation, and continuous method improvements for early and late development projects.

Our service offerings include testing of drug substances, final products, intermediates, and starting materials for large molecule drug products. In addition, we have a range of potency assays, both cell-based and Ligand bidding, that can be applied.

We can help you develop robust and truly MOA-reflective potency assays to accelerate your drug development.

> Learn more

Functional MOA reflective Cell-Based Assays 

Biological activity is a critical quality attribute for biopharmaceuticals and a functional bioassay will, in many cases, give a more intricate answer than a traditional binding assay since the functionality of the compound can be determined, not just a binding interaction.

• Engineered Cell Lines tailored for challenging bioassays
• Assay Ready Cells format enabling easy workflow and maximized control
• innovative solutions tailored to your assay development and manufacturing needs

Discover the benefits of the iLite^® Technology.

> Learn more

FC-Effector Functions

Discover our suite of ADCC/ACDP and CDC Effector cells.

The iLite Fc Effector Reporter Gene Bioassays Portfolio consists of a range of reporter gene cell lines and antigen-specific target cells that can be used in biologically relevant, MOA-reflective assays to measure the Fc effect of antibodies and other biologics that specifically bind and activate Fc receptors.

In addition to this, and to complete the picture, our newly launched CDC Bioassasy, built upon the same technology, provides a versatile and assay-ready platform to assess antibody-mediated Complement-Dependent Cytotoxicity (CDC) accurately.

They are all based on a Luciferase reporter gene system and offer a convenient and powerful way of measuring the efficacy of antibodies to elicit ADCC, ADCP and CDC in vitro.

> Learn more

FUNCTIONAL BIOASSAYS

Complement Products
iLite^® C5a [BM4075]
iLite^® CDC/CD20 (+) Svar Luc [BM5028]

Cytokine responsive
iLite^® RANKL [BM4052]
iLite^® TNF-alpha [BM3044]
iLite^® Type I IFN [BM3049]
iLite^® Type I IFN FAST [BM4049]

Hormone responsive
iLite^® hCG [BM4080]
iLite^® Insulin [BM3060]

Toll-like receptors
iLite^® TLR4 [BM4025]
iLite^® TLR9 [BM6069]

Interleukine responsive
iLite^® IL-2 [BM4002]
iLite^® IL-6 [BM4061]
iLite^® IL-12 [BM4012]
iLite^® IL-23 [BM4023]

Growth Factors
iLite^® VEGF [BM4021]
iLite^® FGF-21 [BM3071]
iLite^® GM-CSF [BM4050]
iLite^® G-CSF [BM4055]

FC EFFECTOR CELLS 

Effector Cells

iLite^® ADCC Effector FcγRIIIa (V) [BM5001]
iLite^® ADCP Effector FcγRIIa [BM5004]

TARGET CELLS

iLite^® CD19 (+) Target [BM5025]
iLite^® CD19 (-) Target [BM5026]
iLite^® CD20 (+) Target [BM5010]
iLite^® CD20 (-) Target [BM5015]
iLite^® EGFR (+) Target [BM5035]
iLite^® EGFR (-) Target [BM5036]
iLite^® HER2 (+) Target [BM5011]
iLite^® HER2 (-) Target [BM5016]
iLite^® mTNF-alpha (+) Target [BM5013]
iLite^® mTNF-alpha (-) Target [BM5014]
iLite^® mVEGF (+) Target [BM5017]
iLite^® mVEGF (-) Target [BM5018]

T-CELL ACTIVATION CELLS 

FUNCTIONAL ASSAYS

Properdin
Complement Factor P Functional Assay [COMPL FPF RUO]

Alternative Pathway
WIESLAB^® Complement Alternative Pathway [COMPLAP330]
WIESLAB^® Complement Alternative Pathway (RUO) [COMPLAP330RUO]

Classical Pathway
WIESLAB^® Complement Classical Pathway [COMPLCP310]
WIESLAB^® Complement Classical Pathway (RUO) [COMPLCP310RUO]

MBL Pathway
WIESLAB^® Complement MBL Pathway [COMPLMP320]
WIESLAB^® Complement MBL Pathway (RUO) [COMPLMP320RUO]

Complement Screen
WIESLAB^® Complement Screen [COMPL300]
WIESLAB^® Complement Screen (RUO) [COMPL300RUO]

BIOMARKER ASSAYS

Complement C4d [COMPL C4d RUO]
Complement TCC [COMPL TCC RUO]
Complement Factor P Quantitative Assay [COMPL FPQ RUO]

CELL-BASED ASSAYS

iLite^® C5a Assay Ready Cells [BM4075]
iLite^® CD20 (+) Svar Luc Assay Ready Cells [BM5028]

DOWNLOAD CASE STUDY

Learn more about the process at Svar of designing, constructing, producing and validating a fit-for purpose potency assay for use in batch release of an AAV based gene therapy drug.

• Complement System Solution Portfolio Brochure
• Cell-based Solutions Portfolio Brochure
• CRO Services Portfolio Brochure

• iLite^® Technology, Cell-based Reporter Gene Assays
• Join us as we explore the future of Gene Therapy
• Custom Development Cell-based Services - adapted to your needs

• How functional iLite cells can be used in the quest to find new treatments